Prognostic Implications of Left Ventricular Hypertrophy

Progress in Cardiovascular Diseases

Volumn 61, Issue 5-6, 2018, Pages 446-455

  Stewart, Merrill H ^a   Lavie, Carl J ^a   Shah, Sangeeta ^a   Englert, Joseph ^a   Gilliland, Yvonne ^a   Qamruddin, Salima ^a   Dinshaw, Homeyar ^a   Cash, Michael ^a   Ventura, Hector ^a   Milani, Richard ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cardiovascular disease; Echocardiography; Hypertension; Left ventricle; Left ventricular geometry; Left ventricular hypertrophy; Left ventricular mass

Indexed keywords

ALISKIREN; ALLOPURINOL; AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RENIN INHIBITOR; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE;

ALL CAUSE MORTALITY; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ENDURANCE TRAINING; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SLEEP DISORDERED BREATHING; SUDDEN CARDIAC DEATH; TRANSVERSE TUBULAR SYSTEM; COMPLICATION; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; PREDICTIVE VALUE; RISK FACTOR;

ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; STROKE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85056478954     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2018.11.002     Document Type: Review

References (138)

1. Levy, D., Labib, S.B., Anderson, K.M., Christiansen, J.C., Kannel, W.B., Castelli, W.P., Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 81:3 (1990), 815–820, 10.1161/01.CIR.81.3.815.
2. Abbasi, A.S., MacAlpin, R.N., Eber, L.M., Pearce, M.L., Left ventricular hypertrophy diagnosed by echocardiography. N Engl J Med 289:3 (1973), 118–121, 10.1056/NEJM197307192890302.
3. Devereux, R.B., Reichek, N., Echocardiographic determination of left ventricular mass in men: anatomic validation of the method. Circulation 55:November (1977), 613–618.
4. Devereux, R.B., Alonso, D.R., Lutas, E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol, 1986, 10.1016/0002-9149(86)90771-X.
5. Reichek, N., Helak, J., Plappert, T., Sutton, M.S., Weber, K.T., Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. Circulation, 1983, 10.1161/01.CIR.67.2.348.
6. Marwick, T.H., Gillebert, T.C., Aurigemma, G., et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging 16:6 (2015), 577–605, 10.1093/ehjci/jev076.
7. Park, S.H., Shub, C., Nobrega, T.P., Bailey, K.R., Seward, J.B., Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr 9:2 (1996), 119–128, 10.1016/S0894-7317(96)90019-X.
8. Lavie, C.J., Milani, R.V., Ventura, H.O., Messerli, F.H., Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol 98:10 (2006), 1396–1399, 10.1016/j.amjcard.2006.06.037.
9. Milani, R.V., Lavie, C.J., Mehra, M.R., Ventura, H.O., Kurtz, J.D., Messerli, F.H., Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol 97:7 (2006), 959–963, 10.1016/j.amjcard.2005.10.030.
10. Lang, R.M., Badano, L.P., Mor-Avi, V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:3 (2015), 233–271, 10.1093/ehjci/jev014.
11. Mor-Avi, V., Sugeng, L., Weinert, L., et al. Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. Circulation 110:13 (2004), 1814–1818, 10.1161/01.CIR.0000142670.65971.5F.
12. Liao, Y., Cooper, R.S., Durazo-Arvizu, R., Mensah, G.A., Ghali, J.K., Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 29:3 (1997), 641–647, 10.1016/S0735-1097(96)00552-9.
13. de Simone, G., Daniels, S.R., Devereux, R.B., et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 20:5 (1992), 1251–1260, 10.1016/0735-1097(92)90385-Z.
14. de Simone, G., Kizer, J.R., Chinali, M., et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens 18:2 (2005), 191–196, 10.1016/j.amjhyper.2004.08.032.
15. Chirinos, J.A., Segers, P., De Buyzere, M.L., et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension 56:1 (2010), 91–98, 10.1161/HYPERTENSIONAHA.110.150250.
16. Rubin, D.N., Yazbek, N., Garcia, M.J., Stewart, W.J., Thomas, J.D., Qualitative and quantitative effects of harmonic echocardiographic imaging on endocardial edge definition and side-lobe artifacts. J Am Soc Echocardiogr 13:11 (2000), 1012–1018, 10.1067/mje.2000.108348.
17. McGavigan, A.D., Dunn, F.G., Goodfield, N.E.R., Secondary harmonic imaging overestimates left ventricular mass compared to fundamental echocardiography. Eur J Echocardiogr 4:3 (2003), 178–181, 10.1016/S1525-2167(02)00164-6.
18. Hirata, K., Watanabe, H., Beppu, S., et al. Pitfalls of echocardiographic measurement in tissue harmonic imaging: in vitro and in vivo study. J Am Soc Echocardiogr 15:10 I (2002), 1038–1044, 10.1067/mje.2002.121537.
19. Spratt, J.C.S., Leslie, S.J., White, A., Fenn, L., Turnbull, C., Northridge, D.B., Harmonic imaging improves estimation of left ventricular mass. Int J Cardiovasc Imaging 20:2 (2004), 107–111.
20. Mansencal, N., Bordachar, P., Chatellier, G., Redheuil, A., Diebold, B., Abergel, E., Comparison of accuracy of left ventricular echocardiographic measurements by fundamental imaging versus second harmonic imaging. Am J Cardiol 91:8 (2003), 1037–1039, 10.1016/S0002-9149(03)00137-1.
21. Turner, S.P., Monaghan, M.J., Tissue harmonic imaging for standard left ventricular measurements: fundamentally flawed?. Eur J Echocardiogr 7:1 (2006), 9–15, 10.1016/j.euje.2005.08.006.
22. Ganau, A., Devereux, R.B., Pickering, T.G., et al. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation 81:1 (1990), 25–36, 10.1161/01.CIR.81.1.25.
23. Heckbert, S.R., Post, W., Pearson, G.D.N., et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging. The Multiethnic Study of Atherosclerosis. J Am Coll Cardiol 48:11 (2006), 2285–2292, 10.1016/j.jacc.2006.03.072.
24. Devereux, R.B., Roman, M.J., de Simone, G., et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation, 1997, 10.1161/01.CIR.96.5.1416.
25. Koide, M., Nagatsu, M., Zile, M.R., et al. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. Circulation, 1997, 10.1161/01.CIR.95.6.1601.
26. Arnett, D.K., Hong, Y., Bella, J.N., et al. Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Am J Hypertens, 2001, 10.1016/S0895-7061(01)02200-2.
27. Post, W.S., Larson, M.G., Myers, R.H., Galderisi, M., Levy, D., Heritability of left ventricular mass: the Framingham Heart Study. Hypertension, 1997, 10.1161/01.HYP.30.5.1025.
28. Petretto, E., Sarwar, R., Grieve, I., et al. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet, 2008, 10.1038/ng.134.
29. Arnett, D.K., Devereux, R.B., Rao, D.C., et al. Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study. J Hypertens, 2009, 10.1097/HJH.0b013e32832be612.
30. López, B., González, A., Querejeta, R., Larman, M., Díez, J., Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48:1 (2006), 89–96, 10.1016/j.jacc.2006.01.077.
31. Díez, J., Querejeta, R., López, B., González, A., Larman, M., Martínez Ubago, J.L., Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:21 (2002), 2512–2517, 10.1161/01.CIR.0000017264.66561.3D.
32. Díez, J., Frohlich, E.D., A translational approach to hypertensive heart disease. Hypertension 55:1 (2010), 1–8, 10.1161/HYPERTENSIONAHA.109.141887.
33. Berk, B.C., Fujiwara, K., Lehoux, S., Review series ECM remodeling in hypertensive heart disease. J Clin Invest 117:3 (2007), 568–575, 10.1172/JCI31044.568.
34. Legrice, I.J., Pope, A.J., Sands, G.B., Whalley, G., Doughty, R.N., Smaill, B.H., Progression of myocardial remodeling and mechanical dysfunction in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 303:11 (2012), H1353–H1365, 10.1152/ajpheart.00748.2011.
35. Matsusaka, H., Ide, T., Matsushima, S., et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension, 2006, 10.1161/01.HYP.0000208840.30778.00.
36. Peterson, J.T., Hallak, H., Johnson, L., et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation, 2001, 10.1161/01.CIR.103.18.2303.
37. Olsen, M.H., Wachtell, K., Hermann, K.L., et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Am Heart J 144:3 (2002), 530–537, 10.1067/mhj.2002.124863.
38. Essick, E.E., Sam, F., Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens, 2011, 2011, 10.4061/2011/346985.
39. Boluyt, M.O., O'Neill, L., Meredith, A.L., et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. Circ Res, 1994, 10.1161/01.RES.75.1.23.
40. Susic, D., Varagic, J., Ahn, J., Matavelli, L., Frohlich, E.D., Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol, 2007, 10.1152/ajpheart.00660.2006.
41. Villari, B., Campbell, S.E., Hess, O.M., et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 22:5 (1993), 1477–1484, 10.1016/0735-1097(93)90560-N.
42. Oktay, A.A., Lavie, C.J., Milani, R.V., et al. Current perspectives on left ventricular geometry in systemic hypertension. Prog Cardiovasc Dis 59:3 (2016), 235–246, 10.1016/j.pcad.2016.09.001.
43. Wei, S., Guo, A., Chen, B., et al. NIH Public Access 107:4 (2011), 520–531, 10.1161/CIRCRESAHA.109.212324.T-tubule.
44. Shah, S.J., Aistrup, G.L., Gupta, D.K., et al. Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. Am J Physiol Heart Circ Physiol, 2014, 10.1152/ajpheart.00642.2013.
45. Crossman, D.J., Young, A.A., Ruygrok, P.N., et al. T-tubule disease: relationship between t-tubule organization and regional contractile performance in human dilated cardiomyopathy. J Mol Cell Cardiol, 2015, 10.1016/j.yjmcc.2015.04.022.
46. Seidel, T., Navankasattusas, S., Ahmad, A., et al. Sheet-like remodeling of the transverse tubular system in human heart failure impairs excitation-contraction coupling and functional recovery by mechanical unloading. Circulation, 2017, 10.1161/CIRCULATIONAHA.116.024470.
47. Manfra, O., Frisk, M., Louch, W.E., Regulation of cardiomyocyte T-tubular structure: opportunities for therapy. Curr Heart Fail Rep 14:3 (2017), 167–178, 10.1007/s11897-017-0329-9.
48. Rimoldi, O., Rosen, S.D., Camici, P.G., The blunting of coronary flow reserve in hypertension with left ventricular hypertrophy is transmural and correlates with systolic blood pressure. J Hypertens, 2014, 10.1097/HJH.0000000000000338.
49. Marcus, M.L., Harrison, D.G., Chilian, W.M., et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 75:1 Pt 2 (1987), I19–I25 http://www.ncbi.nlm.nih.gov/pubmed/2947748.
50. Artham, S.M., Lavie, C.J., Milani, R.V., Patel, D.A., Verma, A., Ventura, H.O., Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 52:2 (2009), 153–167, 10.1016/j.pcad.2009.05.002.
51. Levy, D., Anderson, K.M., Savage, D.D., Kannel, W.B., Christiansen, J.C., Castelli, W.P., Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med, 1988, 10.7326/0003-4819-108-1-7.
52. Palmieri, V., Bella, J.N., Arnett, D.K., et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects Hypertension Genetic Epidemiology Network (HyperGEN) study. Circ Cardiovasc Imaging 103:Box 222 (2001), 102–107.
53. Eguchi, K., Boden-Albala, B., Jin, Z., et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 101:12 (2008), 1787–1791, 10.1016/j.amjcard.2008.02.082.
54. Van Bilsen, M., Daniels, A., Brouwers, O., et al. Hypertension is a conditional factor for the development of cardiac hypertrophy in type 2 diabetic mice. PLoS One, 9(1), 2014, 10.1371/journal.pone.0085078.
55. Okin, P.M., Devereux, R.B., Harris, K.E., et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the losartan intervention for endpoint reduction in hypertension (LIFE). Hypertension 50:5 (2007), 984–990, 10.1161/HYPERTENSIONAHA.107.096818.
56. de Simone, G., Okin, P.M., Gerdts, E., et al. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis 19:9 (2009), 634–640, 10.1016/j.numecd.2008.12.012.
57. Yoneyama, K., Venkatesh, B.A., Wu, C.O., et al. Diabetes mellitus and insulin resistance associate with left ventricular shape and torsion by cardiovascular magnetic resonance imaging in asymptomatic individuals from the multi-ethnic study of atherosclerosis. J Cardiovasc Magn Reson, 20(1), 2018, 53, 10.1186/s12968-018-0472-9.
58. Messerli, F.H., Ventura, H.O., Reisin, E., et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation, 1982, 10.1161/01.CIR.66.1.55.
59. Lavie, C.J., Milani, R.V., Ventura, H.O., Cardenas, G.A., Mehra, M.R., Messerli, F.H., Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol 100:9 (2007), 1460–1464, 10.1016/j.amjcard.2007.06.040.
60. Patel, D.A., Lavie, C.J., Artham, S.M., Milani, R.V., Cardenas, G.A., Ventura, H.O., Effects of left ventricular geometry and obesity on mortality in women with normal ejection fraction. Am J Cardiol 113:5 (2014), 877–880, 10.1016/j.amjcard.2013.11.041.
61. Mancusi, C., Gerdts, E., Losi, M.A., et al. Differential effect of obesity on prevalence of cardiac and carotid target organ damage in hypertension (the Campania Salute Network). Int J Cardiol 244:2017 (2017), 260–264, 10.1016/j.ijcard.2017.06.045.
62. Izzo, R., Losi, M.A., Stabile, E., et al. Development of left ventricular hypertrophy in treated hypertensive outpatients. Hypertension 69:1 (2017), 136–142, 10.1161/HYPERTENSIONAHA.116.08158.
63. Nadruz, W., Claggett, B., Gonçalves, A., et al. Smoking and cardiac structure and function in the elderly: the ARIC study (Atherosclerosis Risk in Communities). Circ Cardiovasc Imaging, 2016, 10.1161/CIRCIMAGING.116.004950.
64. Chami, H.A., Devereux, R.B., Gottdiener, J.S., et al. Left ventricular morphology and systolic function in sleep-disordered breathing the sleep heart health study. Circulation 117:20 (2008), 2599–2607, 10.1161/CIRCULATIONAHA.107.717892.
65. Roca, G.Q., Redline, S., Claggett, B., et al. Sex-specific association of sleep apnea severity with subclinical myocardial injury, ventricular hypertrophy, and heart failure risk in a community-dwelling cohort. Circulation 132:14 (2015), 1329–1337, 10.1161/CIRCULATIONAHA.115.016985.
66. Iwashima, Y., Horio, T., Kamide, K., et al. Additive interaction of metabolic syndrome and chronic kidney disease on cardiac hypertrophy, and risk of cardiovascular disease in hypertension. Am J Hypertens 23:3 (2010), 290–298, 10.1038/ajh.2009.253.
67. Bansal, N., Lin, F., Vittinghoff, E., et al. Estimated GFR and subsequent higher left ventricular mass in young and middle-aged adults with normal kidney function: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Kidney Dis 67:2 (2016), 227–234, 10.1053/j.ajkd.2015.06.024.
68. Lorber, R., Gidding, S.S., Daviglus, M.L., Colangelo, L.A., Liu, K., Gardin, J.M., Influence of systolic blood pressure and body mass index on left ventricular structure in healthy African-American and white young adults: the CARDIA study. J Am Coll Cardiol 41:6 (2003), 955–960, 10.1016/S0735-1097(03)00052-4.
69. Post, W.S., Larson, M.G., Levy, D., Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 90:1 (1994), 179–185, 10.1161/01.CIR.90.1.179.
70. Cuspidi, C., Negri, F., Sala, C., Mancia, G., Masked hypertension and echocardiographic left ventricular hypertrophy: an updated overview. Blood Press Monit 17:1 (2012), 8–13, 10.1097/MBP.0b013e32834f713a.
71. M, G., Z, A., E, A.-R.A.-R., et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 95:6 (1997), 1464–1470 http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/954/CN-00137954/frame.html.
72. Bliziotis, I.A., Destounis, A., Stergiou, G.S., Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens 30:7 (2012), 1289–1299, 10.1097/HJH.0b013e3283531eaf.
73. Abdalla, M., Caughey, M.C., Tanner, R.M., et al. Associations of blood pressure dipping patterns with left ventricular mass and left ventricular hypertrophy in blacks: the Jackson Heart Study. J Am Heart Assoc, 6(4), 2017, 10.1161/JAHA.116.004847.
74. Roman, M.J., Devereux, R.B., Kizer, J.R., et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 50:1 (2007), 197–203, 10.1161/HYPERTENSIONAHA.107.089078.
75. Kollias, A., Lagou, S., Zeniodi, M.E., Boubouchairopoulou, N., Stergiou, G.S., Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. Hypertension 67:1 (2016), 183–190, 10.1161/HYPERTENSIONAHA.115.06066.
76. Weber, T., Wassertheurer, S., Schmidt-Trucksäss, A., et al. Relationship between 24-hour ambulatory central systolic blood pressure and left ventricular mass: a prospective multicenter study. Hypertension 70:6 (2017), 1157–1164, 10.1161/HYPERTENSIONAHA.117.09917.
77. Ganau, A., Devereux, R.B., Roman, M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19:7 (1992), 1550–1558, 10.1016/0735-1097(92)90617-V.
78. Drazner, M.H., The progression of hypertensive heart disease. Circulation 123:3 (2011), 327–334, 10.1161/CIRCULATIONAHA.108.845792.
79. Cuspidi, C., Sala, C., Negri, F., Mancia, G., Morganti, A., Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 26:6 (2012), 343–349, 10.1038/jhh.2011.104.
80. Mancia, G., Carugo, S., Grassi, G., et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Hypertension 39:3 (2002), 744–749, 10.1161/hy0302.104669.
81. Fox, E.R., Taylor, J., Taylor, H., et al. Left ventricular geometric patterns in the Jackson cohort of the atherosclerotic risk in communities (ARIC) study: clinical correlates and influences on systolic and diastolic dysfunction. Am Heart J 153:2 (2007), 238–244, 10.1016/j.ahj.2006.09.013.
82. de Simone, G., Devereux, R.B., Roman, M.J., Alderman, M.H., Laragh, J.H., Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension, 1994, 10.1161/01.HYP.23.5.600.
83. Zabalgoitia, M., Berning, J., Koren, M.J., et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). Am J Cardiol 88:6 (2001), 646–650, 10.1016/S0002-9149(01)01807-0.
84. Lieb, W., Gona, P., Larson, M.G., et al. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging 7:9 (2014), 870–878, 10.1016/j.jcmg.2014.05.008.
85. Milani, R.V., Drazner, M.H., Lavie, C.J., Morin, D.P., Ventura, H.O., Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction. Am J Cardiol 108:7 (2011), 992–996, 10.1016/j.amjcard.2011.05.038.
86. Drazner, M.H., Rame, J.E., Marino, E.K., et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43:12 (2004), 2207–2215, 10.1016/j.jacc.2003.11.064.
87. Rame, J.E., Ramilo, M., Spencer, N., et al. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol 93:2 (2004), 234–237, 10.1016/j.amjcard.2003.09.050.
88. Krishnamoorthy, A., Brown, T., Ayers, C.R., et al. Progression from normal to reduced left ventricular ejection fraction in patients with concentric left ventricular hypertrophy after long-term follow-up. Am J Cardiol 108:7 (2011), 997–1001, 10.1016/j.amjcard.2011.05.037.
89. Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., Castelli, W.P., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med, 1990, 10.1056/NEJM199005313222203.
90. Ghali, J.K., Liao, Y., Cooper, R.S., Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 31:7 (1998), 1635–1640, 10.1016/S0735-1097(98)00131-4.
91. Schillaci, G., Verdecchia, P., Porcellati, C., Cuccurullo, O., Cosco, C., Perticone, F., Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35:2 (2000), 580–586, 10.1161/01.HYP.35.2.580.
92. Verdecchia, P., Carini, G., Circo, A., et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 38:7 (2001), 1829–1835, 10.1016/S0735-1097(01)01663-1.
93. Fox, E.R., Musani, S.K., Samdarshi, T.E., et al. Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans. J Am Heart Assoc 4:2 (2015), 1–9, 10.1161/JAHA.114.001224.
94. Pierdomenico, S.D., Lapenna, D., Cuccurullo, F., Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 21:4 (2008), 464–470, 10.1038/ajh.2008.2.
95. Lavie, C.J., Patel, D.A., Milani, R.V., Ventura, H.O., Shah, S., Gilliland, Y., Impact of echocardiographic left ventricular geometry on clinical prognosis. Prog Cardiovasc Dis 57:1 (2014), 3–9, 10.1016/j.pcad.2014.05.003.
96. Bikkina, M., Levy, D., Evans, J.C., et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 272:1 (1994), 33–36 http://www.ncbi.nlm.nih.gov/pubmed/8007076.
97. Bluemke, D.A., Kronmal, R.A., Lima, J.A.C., et al. The relationship of left ventricular mass and geometry to incident cardiovascular events. The MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 52:25 (2008), 2148–2155, 10.1016/j.jacc.2008.09.014.
98. Verdecchia, P., Reboldi, G.P., Gattobigio, R., et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 41:2 (2003), 218–223, 10.1161/01.HYP.0000052830.02773.E4.
99. Chatterjee, S., Bavishi, C., Sardar, P., et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol 114:7 (2014), 1049–1052, 10.1016/j.amjcard.2014.07.015.
100. Seko, Y., Kato, T., Haruna, T., et al. Association between atrial fibrillation, atrial enlargement, and left ventricular geometric remodeling. Sci Rep, 2018, 10.1038/s41598-018-24875-1.
101. Okin, P.M., Wachtell, K., Devereux, R.B., et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA, 296(10), 2006, 1242, 10.1001/jama.296.10.1242.
102. Wachtell, K., Lehto, M., Gerdts, E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 45:5 (2005), 712–719, 10.1016/j.jacc.2004.10.068.
103. Kannel, W.B., Schatzkin, A., Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 5:6 (1985), 141B–149B, 10.1016/S0735-1097(85)80545-3.
104. Haider, A.W., Larson, M.G., Benjamin, E.J., Levy, D., Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32:5 (1998), 1454–1459, 10.1016/S0735-1097(98)00407-0.
105. Messerli, F.H., Ventura, H.O., Elizardi, D.J., Dunn, F.G., Frohlich, E.D., Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med, 1984, 10.1016/0002-9343(84)90430-3.
106. Aronow, W.S., Epstein, S., Koenigsberg, M., Schwartz, K.S., Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol, 1988, 10.1016/0002-9149(88)90562-0.
107. Kowey, P.R., Friechling, T.D., Sewter, J., et al. Electrophysiological effects of left ventricular hypertrophy effect of calcium and potassium channel blockade. Circulation 83:6 (1991), 2067–2075.
108. Oikarinen, L., Nieminen, M.S., Viitasalo, M., et al. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the losartan intervention for endpoint reduction in hypertension study. Hypertension 43:5 (2004), 1029–1034, 10.1161/01.HYP.0000125230.46080.c6.
109. Mathew, J., Sleight, P., Lonn, E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.[see comment]. Circulation 104:14 (2001), 1615–1621 [11581138].
110. Wachtell, K., Okin, P.M., Olsen, M.H., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE study. Circulation 116:7 (2007), 700–705, 10.1161/CIRCULATIONAHA.106.666594.
111. Aro, A.L., Reinier, K., Phan, D., et al. Left-ventricular geometry and risk of sudden cardiac arrest in patients with preserved or moderately reduced left-ventricular ejection fraction. Europace 19:7 (2017), 1146–1152, 10.1093/europace/euw126.
112. Dahlof, B., Devereux, B.R., Kjeldsen, S.E., Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol. ACC Curr J Rev, 11(5), 2002, 26, 10.1016/S1062-1458(02)00777-8.
113. Devereux, R.B., Dahlöf, B., Gerdts, E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110:11 (2004), 1456–1462, 10.1161/01.CIR.0000141573.44737.5A.
114. Devereux, R.B., Wachtell, K., Gerdts, E., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, 10.1001/jama.292.19.2350.
115. Okin, P.M., Devereux, R.B., Jern, S., Kjeldsen, S.E., Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events., 292(19), 2004, 2343–2349, 10.1001/jama.292.19.2343.
116. Wachtell, K., Bella, J.N., Rokkedal, J., et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 105:9 (2002), 1071–1076, 10.1161/hc0902.104599.
117. Okin, P.M., Devereux, R.B., Harris, K.E., et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med, 2007, 10.7326/0003-4819-147-5-200709040-00006.
118. Moroni, C., Tolone, S., Lopreiato, F., et al. Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment. Eur Rev Med Pharmacol Sci 21:6 (2017), 1323–1328 http://www.ncbi.nlm.nih.gov/pubmed/28387895.
119. Galzerano, D., Tammaro, P., Del Viscovo, L., et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass: a multicenter, randomized, longitudinal study. Am J Hypertens 18:12 (2005), 1563–1569, 10.1016/j.amjhyper.2005.06.011.
120. Boner, G., Cooper, M.E., McCarroll, K., et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia, 2005, 10.1007/s00125-005-1893-1.
121. Group C, Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy. J Hypertens 29:7 (2011), 1439–1447, 10.1097/HJH.0b013e3283480fe9.
122. De Luca, N., Asmar, R.G., London, G.M., O'Rourke, M.F., Safar, M.E., Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 22:8 (2004), 1623–1630, 10.1097/01.hjh.0000125448.28861.fc.
123. Barron, A.J., Hughes, A.D., Sharp, A., et al. Long-term antihypertensive treatment fails to improve E/e′ despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. Hypertension 63:2 (2014), 252–258, 10.1161/HYPERTENSIONAHA.113.01360.
124. Devereux, R.B., Palmieri, V., Sharpe, N., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 104:11 (2001), 1248–1254, 10.1161/hc3601.095927.
125. Klingbeil, A.U., Schneider, M., Martus, P., Messerli, F.H., Schmieder, R.E., A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:1 (2003), 41–46, 10.1016/S0002-9343(03)00158-X.
126. Baggish, A.L., Wang, F., Weiner, R.B., et al. Training-specific changes in cardiac structure and function: a prospective and longitudinal assessment of competitive athletes. J Appl Physiol 104:4 (2008), 1121–1128, 10.1152/japplphysiol.01170.2007.
127. Palatini, P., Visentin, P., Dorigatti, F., et al. Regular physical activity prevents development of left ventricular hypertrophy in hypertension. Eur Heart J 30:2 (2009), 225–232, 10.1093/eurheartj/ehn533.
128. Leichman, J.G., Wilson, E.B., Scarborough, T., et al. Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery. Am J Med 121:11 (2008), 966–973, 10.1016/j.amjmed.2008.06.033.
129. Cuspidi, C., Rescaldani, M., Tadic, M., Sala, C., Grassi, G., Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis. Am J Hypertens 27:2 (2014), 146–156, 10.1093/ajh/hpt215.
130. Feniman Stefano, G.M.M., Zanati Basan, S.G., Stefano, L.M., et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis 9:4 (2015), 158–167, 10.1177/1753944715591448.
131. Gu, J., Fan, Y.Q., Han, Z.H., et al. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. Int J Cardiol 220:2016 (2016), 56–60, 10.1016/j.ijcard.2016.06.190.
132. Engberding, N., Spiekermann, S., Schaefer, A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 110:15 (2004), 2175–2179, 10.1161/01.CIR.0000144303.24894.1C.
133. Kao, M.P., Ang, D.S., Gandy, S.J., et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol, 2011, 10.1681/ASN.2010111185.
134. Rekhraj, S., Gandy, S.J., Szwejkowski, B.R., et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 61:9 (2013), 926–932, 10.1016/j.jacc.2012.09.066.
135. Solomon, S.D., Appelbaum, E., Manning, W.J., et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119:4 (2009), 530–537, 10.1161/CIRCULATIONAHA.108.826214.
136. Schmieder, R.E., Wagner, F., Mayr, M., et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J 38:44 (2017), 3308–3317, 10.1093/eurheartj/ehx525.
137. P, H.C., R, S.D., H, C., et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail 18:6 (2016), 703–712, 10.1002/ejhf.502.
138. Zamani, P., Akers, S., Soto-Calderon, H., et al. Isosorbide dinitrate, with or without hydralazine, does not reduce wave reflections, left ventricular hypertrophy, or myocardial fibrosis in patients with heart failure with preserved ejection fraction. J Am Heart Assoc 6:2 (2017), 1–16, 10.1161/JAHA.116.004262.